Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials

Wei Qu; Li Yao; Xiaodan Liu; Tianhua Xu; Binyao Tian

doi:10.3389/fphar.2021.630820

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials

Front Pharmacol. 2021 Mar 12:12:630820. doi: 10.3389/fphar.2021.630820. eCollection 2021.

Authors

Wei Qu¹, Li Yao¹, Xiaodan Liu¹, Tianhua Xu¹, Binyao Tian¹

Affiliation

¹ Department of Nephrology, the First Hospital of China Medical University, Shenyang, China.

Abstract

Background: This study aimed to explore the effects of sodium-glucose co-transporter 2 (SGLT2) on hemoglobin levels in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. Methods: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the China National Knowledge Infrastructure database, Wanfang Digital Periodicals Database (WFDP) and the Chinese Biological and Medical database (CBM) were searched for randomized trials of SGLT2 inhibitors in patients with T2DM and chronic kidney disease up to July 25, 2020. A total of four studies that included 19,259 patients were identified. Results: Compared to control patients, SGLT2 inhibitors were shown to increase hemoglobin levels in patients with T2DM and chronic kidney disease (standard mean difference = 0.70, 95% CI, 0.59-0.82, p < 0.0001). Conclusion: SGLT2 inhibitors may bring additional benefits to patients with T2DM and chronic kidney disease.

Keywords: SGLT2 inhibitors; chronic kidney disease; hemoglobin; meta-analysis; type 2 diabetes.